Drug compositions exhibiting thrombopoietin agonism

摘要

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein X<1> is optionally substituted heteroaryl or the like; Y<1> is -NRCO-(CH2)0-2- or the like (wherein R is a hydrogen or the like); Z<1> is optionally substituted arylene or the like; and A<1> is a ring represeted by general formula (II) or (III):